ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’
Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.
Watch
Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer
Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in terms of prostate cancer therapy.
Discussing the Mission of CURE With Our Former and New Editors-In-Chief
Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.
Targeted Axillary Dissection Offers a Precise Option in Breast Cancer
Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.
Guiding Patients Through Shared Decision-Making in Breast Cancer Care
Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.
Understanding the Best Practices Associated With CDK4/6 Therapy in Breast Cancer
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
How the FDA Approval of Imfinzi Advances Small Cell Lung Cancer Treatment
The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.
FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.
What the FDA Approval of Bizengri Means for Patients With NRG1-Positive NSCLC
The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.
What’s On the Horizon for Small Cell Lung Cancer Research?
On the heels of two FDA approvals in lung cancer treatments, what innovations are next?
A Patient’s Journey With Colon Cancer and Her Advocacy Mission
Melissa Ursini, diagnosed with stage 2 colon cancer, shares her journey to raise awareness and encourage early detection through colonoscopies.
Colostomies and Colon Cancer, a Lifesaving Choice, Not a Last Resort
Dr. Andreas M. Kaiser explains how a colostomy may preserve a patient’s health and help to avoid colorectal cancer complications.
Better Understanding Genetic Mutations Influence in Cancer Care
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Expert Explains Safety of Krazati Regimen For Treating Colorectal Cancer
Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.
Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Off-The-Shelf CAR T Therapy Elicits Responses in Large B-Cell Lymphoma
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
A Study Investigates If CAR T Therapy Directly Causes Secondary Malignancies
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Minimal Residual Disease Testing’s Variability Across Cancer Types
Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics.
What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar
An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.
Delving Into Clinical Research For Patients With Breast Cancer
Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.
Clinical Trials to Watch in Triple-Negative Breast Cancer
An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.
Understanding Biliary Tract Cancer and The Current Standard of Care
An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.
What Patients With Cancer Should Know About DPD Deficiency Prior to Chemo
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it.
GAP Triplet May Be Less Safe Than Doublet Chemo in Biliary Tract Cancer
An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet and increased severe side effects.
COSMIC-313 Trial Lead Breaks Down Treatment Intensification in RCC
Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.
Personalized Medicine Makes Strides Across the GU Oncology Treatment Space
Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.
The Importance of Genetic Testing in Metastatic Colorectal Cancer
An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments.
Personalized Cancer Vaccine Demonstrates Responses in Kidney Cancer
Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a vaccine.
Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.
